vTv Therapeutics Announces Initiation of Study Evaluating TTP399's Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Stock Information for vTv Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.